Paclitaxel encapsulated in cationic liposomes: A new option for neovascular targeting for the treatment of prostate cancer

Oncology Reports

Volumn 22, Issue 2, 2009, Pages 321-326

  Bode, Christian ^a   Trojan, Lutz ^a   Weiss, Christel ^a   Kraenzlin, Bettina ^a   Michaelis, Uwe ^b   Teifel, Michael ^c   Alken, Peter ^a   Michel, Maurice Stephan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MediGene AG   (Germany)

^c Æterna Zentaris GmbH   (Germany)

Author keywords

Cationic liposomes; Chemotherapy; Neovascular targeting; Prostate cancer

Indexed keywords

GLUCOSE; LIPOSOME; PACLITAXEL;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENCAPSULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; LUNG METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RAT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; LIPOSOMES; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; RATS;

EID: 68349121331     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000440     Document Type: Article

References (29)

1. Farkas A, Schneider D, Perrotti M, et al: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 52: 444-449, 1998.
2. Sharifi N, Dahut WL, Steinberg SM, et al: A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 96: 985-989, 2005.
3. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71, 1992.
4. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
5. Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45: 136-139, 1982.
6. Borgstrom P, Bourdon MA, Hillan KJ, et al: Neutralizing antivascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35: 1-10, 1998.
7. Miki T, Nonomura N, Nozawa M, et al: Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line. J Urol 160: 210-213, 1998.
8. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996.
9. Felgner PL, Gadek TR, Holm M, et al: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417, 1987.
10. Perez-Soler R: Liposomes as carriers of antitumor agents: toward a clinical reality. Cancer Treat Rev 16: 67-82, 1989.
11. Poste G, Bucana C, Raz A, et al: Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 42: 1412-1422, 1982.
12. Ran S, Downes A and Thorpe PE: Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62: 6132-6140, 2002.
13. Thurston G, McLean JW, Rizen M, et al: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101: 1401-1413, 1998.
14. Schmitt-Sody M, Strieth S, Krasnici S, et al: Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 9: 2335-2341, 2003.
15. Eichhorn ME, Luedemann S, Strieth S, et al: Cationic lipid complexed camptothecin (EndoTAG((R))-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther 6: 920-929, 2007.
16. Smolev JK, Heston WD, Scott WW, et al: Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. Cancer Treat Rep 61: 273-287, 1977.
17. Isaacs JT, Isaacs WB, Feitz WF, et al: Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986.
18. Hasan J, Byers R and Jayson GC: Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86: 1566-1577, 2002.
19. Sonpavde G and Hutson TE: New approaches in hormone refractory prostate cancer. Am J Clin Oncol 29: 196-201, 2006.
20. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
21. Petrylak DP, Macarthur RB, O'Connor J, et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17: 958-967, 1999.
22. Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19: 44-53, 2001.
23. Zhu N, Liggitt D, Liu Y, et al: Systemic gene expression after intravenous DNA delivery into adult mice. Science 261: 209-211, 1993.
24. Krasnici S, Werner A, Eichhorn ME, et al: Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 105: 561-567, 2003.
25. Kadota T, Chikazawa H, Kondoh H, et al: [Toxicity studies of paclitaxel. (II)-One-month intermittent intravenous toxicity in rats]. J Toxicol Sci 19 (Suppl 1): 11-34, 1994.
26. Strieth S, Eichhorn ME, Sauer B, et al: Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 110: 117-124, 2004.
27. Kunstfeld R, Wickenhauser G, Michaelis U, et al: Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a 'humanized' SCID mouse model. J Invest Dermatol 120: 476-482, 2003.
28. Lazan DW, Heston WD, Kadmon D, et al: Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis (3,5-dioxopiperazin-1-yl)propane. Cancer Res 42: 1390-1394, 1982.
29. Dass CR: Immunostimulatory activity of cationic-lipid-nucleicacid complexes against cancer. J Cancer Res Clin Oncol 128: 177-181, 2002.